Peptide Report
Tesamorelin Peptide Report
Catalog report for Tesamorelin, generated from Peptide Stacks product data and linked to the matching PeptideReports protocol page when available.
Current Price$59.99 – $150.00 CAD
Common Uses
People commonly discuss Tesamorelin for body-composition routines, growth-hormone pathway support, and visceral-fat reduction conversations.
How It Works
Tesamorelin is a GHRH analog. It works at pituitary GHRH receptors to stimulate endogenous growth-hormone release, which can increase downstream IGF-1 signaling involved in body-composition and metabolic research.
Storage
Powder form: In lyophilized powder form, Tesamorelin is generally kept sealed, dry, protected from direct light, and refrigerated unless the product label or certificate of analysis gives different handling instructions. Avoid leaving vials in hot rooms, vehicles, direct sunlight, or other temperature swings, because moisture, heat, and light are the main storage conditions people try to control before reconstitution.
Reconstituted: After reconstitution, Tesamorelin should generally be treated as more sensitive: keep it refrigerated, minimize unnecessary handling, avoid shaking, and use clean handling practices each time the vial is accessed. Follow the product label, protocol page, and any pharmacy or lab guidance for beyond-use timing; if the solution changes color, becomes cloudy, develops particles, or the vial integrity is questionable, it should not be used.
Protocol
The full Tesamorelin protocol is included below. The standalone protocol page remains available if you want to open it separately.
Open Standalone Protocol
Scope
Preparation examples, syringe conversion, community-reported patterns and important limitations.
Available strengths: 5, 10 and 20 MG
Preparation Examples
These are calculation examples only. The concentration assumptions below are explicit so syringe units are never separated from vial strength and diluent volume.
| Setup |
Diluent |
Concentration |
Unit conversion |
| 5 MG vial – 2 mL example |
Add 2 mL bacteriostatic water |
2.5 mg/mL |
Each U-100 unit = 25 mcg |
| 20 MG vial – 2 mL example |
Add 2 mL bacteriostatic water |
10 mg/mL |
Each U-100 unit = 100 mcg |
Syringe Conversion
| Reported amount |
5 MG setup |
20 MG setup |
| 500 mcg |
20 units |
5 units |
| 1 mg |
40 units |
10 units |
| 2 mg |
80 units |
20 units |
| 3 mg |
120 units |
30 units |
Always recalculate from the actual vial strength and diluent volume. A U-100 unit is 0.01 mL; it is not a dose by itself.
Community-Reported Patterns
| Recurring report |
Frequency seen |
Context in reports |
| 1 mg |
Once daily |
Lower community reports |
| 2 mg |
Once daily |
Prescription-label-aligned discussions |
| 2-3 mg |
Once daily in some reports |
Higher experimental use |
Observations
- Community discussions most often centered on visceral-fat reduction, body composition and growth-hormone-axis goals.
- The amount, frequency, route and cycle length varied substantially between reports.
- Reported outcomes were commonly confounded by diet, training, other products or existing treatment.
Caveats
- Prescription tesamorelin has indication-specific contraindications and requires monitoring of IGF-1 and glucose; community use is not equivalent.
- Community reports are uncontrolled anecdotes and do not establish an appropriate dose, safety, product identity, purity or efficacy.